Evommune, Inc. (EVMN)Healthcare | Biotechnology | Palo Alto, United States | NYSE
5.88 USD
-0.17
(-2.810%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8 a.m. EDT
The investment case for Evommune is currently broken by a catastrophic failure in its clinical pipeline. The company recently missed its primary goal in a Phase IIb study for urticaria, which has likely triggered the massive put buying seen in the options chain as investors flee the stock. While the management team has shown some skin in the game with recent purchases, the company remains deeply cash-burn prone with negative operating cash flow and no dividends to offset the capital destruction. The balance sheet provides some runway, but without a successful pivot or new data readout, the business faces a high risk of dilution or insolvency. The statistical models correctly flag a weak downward trend, confirming that the market is pricing in further distress rather than a turnaround. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.184242 |
| MSTL | 0.185144 |
| AutoARIMA | 0.187081 |
| AutoETS | 0.187291 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 1.61 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.119 |
| Excess Kurtosis | -0.75 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.109 |
| Revenue per Share | 0.438 |
| Market Cap | 213,397,616 |
| Forward P/E | -1.66 |
| Website | https://www.evommune.com |
As of Oct. 10, 2026, 8 a.m. EDT: Speculators are aggressively positioning for downside protection with heavy volume in out-of-the-money puts (strikes 7.5 and 10.0) expiring in February 2027, indicating a strong bearish sentiment. Conversely, call activity is negligible and concentrated in deep out-of-the-money strikes, suggesting minimal speculative hope for a near-term recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.7093426 |
| Address1 | 1,891 Page Mill Road |
| All Time High | 33.2 |
| All Time Low | 5.85 |
| Ask | 0.0 |
| Ask Size | 500 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 1,091,450 |
| Average Daily Volume3 Month | 687,601 |
| Average Volume | 687,601 |
| Average Volume10Days | 1,091,450 |
| Bid | 0.0 |
| Bid Size | 600 |
| Board Risk | 8 |
| Book Value | 7.651 |
| City | Palo Alto |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.88 |
| Current Ratio | 11.68 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 6.05 |
| Day Low | 5.85 |
| Debt To Equity | 3.109 |
| Display Name | Evommune |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,794,859,200 |
| Earnings Timestamp Start | 1,794,859,200 |
| Ebitda | -100,356,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.212 |
| Enterprise To Revenue | 2.123 |
| Enterprise Value | 21,233,624 |
| Eps Current Year | -3.48188 |
| Eps Forward | -3.54182 |
| Eps Trailing Twelve Months | -3.75 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 20 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 10.9618 |
| Fifty Day Average Change | -5.0817995 |
| Fifty Day Average Change Percent | -0.46359172 |
| Fifty Two Week Change Percent | -70.93426 |
| Fifty Two Week High | 33.2 |
| Fifty Two Week High Change | -27.32 |
| Fifty Two Week High Change Percent | -0.82289153 |
| Fifty Two Week Low | 5.85 |
| Fifty Two Week Low Change | 0.03000021 |
| Fifty Two Week Low Change Percent | 0.005128241 |
| Fifty Two Week Range | 5.85 - 33.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,762,439,400,000 |
| Float Shares | 19,882,997 |
| Forward Eps | -3.54182 |
| Forward P E | -1.6601634 |
| Free Cashflow | -39,127,752 |
| Full Exchange Name | NYSE |
| Full Time Employees | 48 |
| Fullday Change | -0.17000008 |
| Fullday Change Percent | -2.8099186 |
| Fullday Price | 6.05 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 1.0 |
| Gross Profits | 10,000,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03153 |
| Held Percent Institutions | 1.14386 |
| Implied Shares Outstanding | 36,292,113 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California. |
| Market | us_market |
| Market Cap | 213,397,616 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_695398216 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -94,668,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 318,281,831 |
| Number Of Analyst Opinions | 9 |
| Open | 6.05 |
| Operating Cashflow | -74,153,000 |
| Operating Margins | -10.1894 |
| Overall Risk | 8 |
| Phone | (925) 247-4481 |
| Pre Market Change | 0.17000008 |
| Pre Market Change Percent | 2.8911576 |
| Pre Market Price | 6.05 |
| Pre Market Time | 1,791,981,814 |
| Previous Close | 6.05 |
| Price Eps Current Year | -1.6887429 |
| Price Hint | 2 |
| Price To Book | 0.76852703 |
| Price To Sales Trailing12 Months | 21.339762 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.482 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.83333 |
| Region | US |
| Regular Market Change | -0.17 |
| Regular Market Change Percent | -2.80992 |
| Regular Market Day High | 6.05 |
| Regular Market Day Low | 5.85 |
| Regular Market Day Range | 5.85 - 6.05 |
| Regular Market Open | 6.05 |
| Regular Market Previous Close | 6.05 |
| Regular Market Price | 5.88 |
| Regular Market Time | 1,791,921,602 |
| Regular Market Volume | 804,866 |
| Return On Assets | -0.31989 |
| Return On Equity | -0.52107 |
| Revenue Per Share | 0.438 |
| Sand P52 Week Change | 0.17004645 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 36,292,113 |
| Shares Percent Shares Out | 0.0797 |
| Shares Short | 2,892,407 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,364,904 |
| Short Name | Evommune, Inc. |
| Short Percent Of Float | 0.118 |
| Short Ratio | 3.64 |
| Source Interval | 15 |
| State | CA |
| Symbol | EVMN |
| Target High Price | 30.0 |
| Target Low Price | 8.0 |
| Target Mean Price | 22.33333 |
| Target Median Price | 22.0 |
| Total Cash | 200,792,992 |
| Total Cash Per Share | 5.533 |
| Total Debt | 8,629,000 |
| Total Revenue | 10,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.75 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.5755 |
| Two Hundred Day Average Change | -12.6955 |
| Two Hundred Day Average Change Percent | -0.68345404 |
| Type Disp | Equity |
| Volume | 804,866 |
| Website | https://www.evommune.com |
| Zip | 94,304 |